The Institute for In Vitro Sciences (IIVS), with an established track record in the validation of alternatives to animal testing, is teaming up with BASF and Givaudan to validate an improved skin sensitization reactivity method to address the needs of toxicologists and regulators. Scientist ... more
BASF Venture Capital invests in German biotechnology company baseclick
Group of investors invests €1.2 million
baseclick GmbH, a spin-off from BASF SE and Ludwig-Maximilians-Universität Munich, raised an additional €1.2 million from private investors and BASF Venture Capital, the largest single investor, in the second round of financing. The start-up company baseclick GmbH, founded in the year 2008, is located in Tutzing, Germany, and holds technology patents in labeling processes of deoxyribonucleic acid (DNA) .
“We will use the capital raised to expand our existing activities in DNA-technologies,” says Dr. Thomas Frischmuth, General Manager of baseclick GmbH. In addition, the company will build up a business for diagnostic technologies.
The baseclick technology allows users to label multiple dye molecules on DNA strands in a sequence-specific manner. This process is more efficient, more cost effective and simpler than conventional technologies. The attachment of multiple dyes enables several or highly complex analyses to be carried out in a single operation. Applications include analyses for pathogens like HIV, hepatitis, or even tumor cells. The technique can also be used to detect mutations in human, animal and plant genomes.
The baseclick technology is based on click chemistry research by Professor Barry Sharpless (Nobel Prize in Chemistry, 2001) of The Scripps Research Institute, La Jolla, California. Professor Thomas Carell of Ludwig-Maximilians-Universität Munich, Germany, has advanced the technology so that nucleic acids can be modified. baseclick GmbH has obtained a worldwide license from The Scripps Research Institute to practice click chemistry in its field of research.
- deoxyribonucleic acid
BASF announced that its U.S. affiliate, BASF Corporation, has entered into an agreement to commence a cash tender offer for all of the outstanding shares of common stock of the biotechnology company Verenium Corporation (VRNM) for US$4.00 per share. Based on all outstanding shares and inclu ... more
Promega and BASF have jointly developed an alternative method to animal studies that can reliably detect the allergenic potential of substances. Using a newly developed cell line, the reaction of skin cells to allergenic substances can now be demonstrated in the test tube. Allergic skin rea ... more
The rapid spread of the newly emerging SARS-CoV-2 virus variant B.1.1.7 in Great Britain and other countries shows, changes in the genome of the SARS-CoV-2 virus can lead to new biological properties. Most of the approximately 12,000 mutations in the genome of the SARS-CoV-2 virus that hav ... more
For the first time, baseclick GmbH, a start-up company spun off from BASF SE and Ludwig-Maximilians-Universität Munich, is making its newly developed process for labeling nucleic acids (DNA and RNA) available to customers. The company recently signed licensing agreements for this technology ... more
- 1Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 2Fluorescence microscopy at highest spatial and temporal resolution
- 3The Mechanics of the Immune System
- 4Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis
- 5Quick look under the skin
- 6New ion trap to create the world's most accurate mass spectrometer
- 7How does your computer smell?
- 8Clocking electron movements inside an atom
- 9Sartorius closes 2020 with strong growth
- 10A clear path to better insights into biomolecules
- Speeding up sequence alignment across the tree of life
- Detection of viruses, bacteria and toxins in real time
- DESY X-ray lightsource identifies promising candidates for COVID drugs
- First 3D Images of a Giant Molecule
- NanoTemper Technologies teams up with PharmAI to help researchers spot game-changing drug candidates from millions of possibilities